Clinical Trials
11 trialsNCT06897579 2026-04-28
Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Terminated
NCT04699838 2026-01-02
Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer
Big Ten Cancer Research Consortium
Phase 2 Recruiting
NCT00057837 2023-07-05
Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT05896059 2023-06-09
A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Anlotinib as Maintenance Therapy for ES-SCLC
Zhejiang Cancer Hospital
Phase 2 Unknown
NCT04933175 2021-06-21
Fluzopalil in Combination With Anlotinib for Extensive Small-cell Lung Cancer
Fujian Provincial Hospital
Phase 2 Unknown
NCT04790539 2021-03-10
a Study of SHR1210 in Combination With Paclitaxel-albumin and Carboplatin in Extensive Stage Small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Unknown
NCT04213937 2019-12-30
Nab-paclitaxel Versus Topotecan As Second-Line Treatment for Patients With Extensive Stage Small Cell Lung Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Unknown
NCT02972320 2016-11-23
Extensive Stage Sclc Patients Who Were Benefit From First-line Treatment Accept Temozolomide Maintain Therapeutic
China Medical University, China
Phase 2 Unknown
NCT00118235 2014-06-17
Cisplatin, Irinotecan, and Bevacizumab, in Treating Patients With Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00079040 2014-05-14
Cisplatin, Etoposide, and Bevacizumab in Treating Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00028028 2013-02-28
CCI-779 in Treating Patients With Extensive-Stage Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Completed